RxDoctor Payments Data

Chirag Rana, MD

Cardiovascular Disease · Fair Lawn, NJNPI 1902216419

Payments from drug & device makers

$1,835in general payments, 2019–2025

Across 55 payments — averaging $33.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$333
  • Medtronic$318
  • Novo Nordisk$181
  • Abbott$150
  • E.r. Squibb & Sons, L.L.C.$133
  • Boehringer Ingelheim$121
  • plus $599 from 13 others

What the payments were for

  • Food & beverage$1,61688%
  • Education$22012%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,835 in reported general payments places this provider in the 35th percentile of 1,006 cardiovascular disease providers in New Jersey.

See all cardiovascular disease providers in New Jersey

Medicare billing

Part B allowed, 2024
$244,621
Medicare patients
609
Services billed
2,662

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban188$202,267
Repatha SureclickEvolocumab47$42,067
EntrestoSacubitril/Valsartan34$30,354
Praluent PenAlirocumab22$27,232
XareltoRivaroxaban22$22,947
BrilintaTicagrelor15$8,649
Ranolazine ErRanolazine21$3,672
Metoprolol Succinate262$3,423
Atorvastatin Calcium245$2,842
Rosuvastatin Calcium161$2,268
Amlodipine Besylate326$2,066
FenofibrateFenofibrate Nanocrystallized56$1,372
Carvedilol158$1,182
Midodrine Hcl13$853
Losartan Potassium87$835

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$63$202,267188 claims
NovartisEntresto$76$30,35434 claims
Johnson & JohnsonXarelto$77$22,94722 claims
AstraZenecaBrilinta$333$8,64915 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 1,006 cardiovascular disease providers in New Jersey.

Other cardiovascular disease in Fair Lawn

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →